神経学臨床試験市場レポート：2023-2033
Neurology Clinical Trials Market Report 2023-2033
レポート詳細
神経学の臨床試験市場レポート2023-2033年 ： 本レポートは、業界とその基礎となる原動力をよりよく理解することを望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものと... もっと見る
※上記価格は部署ライセンス（Departmental licence）価格です。
その他の価格についてはデータリソースまでお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。
サマリー
レポート詳細
神経学の臨床試験市場レポート2023-2033年： 本レポートは、業界とその基礎となる原動力をよりよく理解することを望むなら、新たな収益ポケットを目指す大手企業にとって貴重なものとなるでしょう。本レポートは、異業種への進出や新規地域での既存事業の拡大を目指す企業にとって有益なものとなるでしょう。
ウェアラブルデバイス、モバイルヘルスアプリケーション、遠隔モニタリングツールの導入は、患者の転帰や疾患の進行を瞬時にモニタリングすることを容易にし、データ収集に大きなパラダイムシフトをもたらした。これらの技術は、継続的で偏りのない豊富なデータを提供し、それによって試験結果の正確性と信頼性を高めている。加えて、機能的MRIやPETスキャンを含む神経画像診断法の発展は、脳の操作や相互連結に関する比類ない視点を提供する。テクノロジーを臨床試験プロセスに取り入れることは、効率を高めるだけでなく、神経疾患を理解するための新たな機会を提供する。
市場調査レポートを購入する前にすべき質問とは？
- 神経学臨床試験市場はどのように進化しているのか？
- 神経学臨床試験市場の推進要因と阻害要因は何か？
- 神経学臨床試験サブマーケットの各セグメントは予測期間中にどのように成長し、2033年にはどれくらいの売上を占めるようになるのか？
- 2023年から2033年にかけて、神経学臨床試験の各サブマーケットの市場シェアはどのように推移するのか？
- 2023年から2033年にかけて市場全体を牽引する主な要因は何か？
- 主要な神経学臨床試験市場はマクロ経済ダイナミクスに大枠で追随するのか、それとも個々の国内市場が他を凌駕するのか？
- 2033年までに各国市場のシェアはどのように変化し、2033年に市場をリードするのはどの地域か？
- 主要プレイヤーは誰で、予測期間中の見通しは？
- これらの主要企業の神経学臨床試験プロジェクトは何か？
- 2023年から2033年の間に、業界はどのように発展していくのか？現在行われている
現在および今後10年間に実施される神経学臨床試験プロジェクトはどのような意味を持つのか？
- 神経学臨床試験市場をさらに拡大するために、製品の商業化の必要性は高まっているか？
- 神経学臨床試験市場はどこへ向かっているのか。
- 新製品やサービスラインに対する最適な投資オプションは何か？
- 企業を新たな成長軌道に乗せ、C-suiteに移行させるための重要な展望とは？
このことが神経学臨床試験市場に現在、そして今後10年間でどのような影響を与えるかを見極める必要がある：
- 262ページにわたる本レポートは、107の表と153の図表で構成されています。
- 本レポートでは、業界における主要な有利分野を取り上げているため、今すぐターゲットを絞ることができます。
- 本レポートには、世界、地域、国の売上と成長に関する詳細な分析が含まれています。
- 競合他社が成功した主なトレンド、変化、収益予測をハイライトしています。
本レポートは、神経学臨床試験市場が今後10年間にどのように発展するか、またCOVID-19の景気後退と好転の変動に合わせてどのように発展するかをお伝えします。この市場は過去10年間のどの時点よりも今が重要である。
2033年までの予測やその他の分析から、商業的な展望が明らかになる
- 2033年までの収益予測に加え、直近の業績、成長率、市場シェアもご覧いただけます。
- ビジネスの展望と展開に関する独自の分析をご覧いただけます。
- 定性的分析（市場ダイナミクス、促進要因、機会、阻害要因など）、ポーターのファイブフォース分析、PEST分析、最近の動向をご覧いただけます。
本レポートには、COVID-19が業界と貴社にどのような影響を与えるかについてのデータ分析と貴重な洞察が含まれている。本レポートでは、COVID-19の4つの回収パターンとその影響、すなわち「V」、「L」、「W」、「U」について論じている。
レポート対象セグメント
研究デザイン
- 介入研究
- 観察研究
- 拡張アクセス
適応症
- てんかん
- 脳卒中
- アルツハイマー病（AD）
- パーキンソン病（PD）
- 外傷性脳損傷（TBI）
- その他
フェーズ
- フェーズI
- フェーズII
- フェーズIII
- フェーズIV
世界市場全体とセグメント別の収益予測に加え、5つの地域と20の主要国市場の収益予測も掲載しています：
北米
- アメリカ
- カナダ
欧州
- ドイツ
- 英国
- フランス
- イタリア
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他のアジア太平洋地域
ラテンアメリカ
- ブラジル
- メキシコ
- その他のラテンアメリカ
MEA
- GCC
- 南アフリカ
- その他のMEA
また、神経学臨床試験市場の2023年から2033年にかけての主要企業のプロファイルも掲載しており、これらの企業の事業のこのセグメントに焦点を当てています。
主要企業と市場成長の可能性
・ AbbVie Inc.
・ Alector, Inc.
・ Annovis Bio
・ AstraZeneca
・ Athira Pharma, Inc.
・ Biogen
・ Charles River Laboratories
・ Eisai Inc.
・ Eli Lilly and Company
・ ICON plc
・ IQVIA
・ Laboratory Drug Development
・ Medpace Holdings, Inc.
・ Merck ＆ Co., Inc.
・ Novartis AG
・ Sanofi
・ Supernus Pharmaceuticals, Inc.
・ Syneos Health
・ Teva Pharmaceutical Industries Ltd.
神経学臨床試験市場全体の世界売上高（2023年～2033年）は、金額ベースで2023年に96億米ドルを超えると弊社では予測しています。2033年まで力強い収益成長を予測。本調査では、最も大きな可能性を秘めた組織を特定します。各組織の能力、進捗状況、商業的展望を把握し、一歩先を行くための一助としてください。
神経学の臨床試験市場、2023-2033年レポートはどのようにお役に立ちますか？
要約すると、260ページを超えるこのレポートは、以下の知識を提供する：
- 神経学臨床試験市場の2023年から2033年までの収益予測、試験デザイン、適応症、フェーズごとの予測、世界および地域レベルでの各予測 - 業界の展望を発見し、投資と収益に最も有利な場所を見つけます。
- 5つの地域と20の主要国市場の2033年までの収益予測 - 北米、欧州、アジア太平洋、中南米、MEAの神経学臨床試験市場2023年から2033年までの市場予測をご覧ください。また、米国、カナダ、メキシコ、ブラジル、ドイツ、フランス、英国、イタリア、中国、インド、日本、オーストラリアなどの主要経済圏の市場も予測しています。
- 既存企業および市場参入を目指す企業の展望 - 神経学臨床試験市場に関わる主要企業19社の企業プロファイルを含む、2023年から2033年までの市場。
独自の予測による定量的・定性的分析をご覧ください。私たちのレポートだけに含まれる情報を入手し、貴重なビジネスインテリジェンスで情報を得ることができます。
他にはない情報
私たちの新しいレポートがあれば、知識に遅れをとったり、チャンスを逃したりする可能性が低くなります。弊社の調査レポートが貴社の調査、分析、意思決定にどのように役立つかをご覧ください。Visiongainの調査は、神経学臨床試験市場2023年から2033年、市場をリードする企業の商業分析を必要とするすべての人のためのものです。データ、トレンド、予測をご覧いただけます。
ページTOPに戻る
目次
目次
1 レポート概要
1.1 研究の目的
1.2 神経学臨床試験市場の紹介
1.3 本レポートの内容
1.4 本レポートを読むべき理由
1.5 本分析レポートが回答する主な質問は以下の通り
1.6 本レポートの対象者
1.7 方法論
1.7.1 市場の定義
1.7.2 市場評価・予測手法
1.7.3 データの検証
1.7.3.1 一次調査
1.7.3.2 セカンダリーリサーチ
1.8 よくある質問（FAQ）
1.9 Visiongainの関連レポート
1.10 Visiongainについて
2 エグゼクティブ・サマリー
3 市場概要
3.1 主要な調査結果
3.2 市場ダイナミクス
3.2.1 市場促進要因
3.2.1.1 神経疾患の有病率の増加
3.2.1.2 臨床研究における新技術の採用拡大
3.2.1.3 神経学臨床研究サービスを提供する CRO の数の増加
3.2.1.4 神経学研究のための資金調達の増加
3.2.2 市場抑制要因
3.2.2.1 神経学臨床研究に関連する高コスト
3.2.2.2 高い失敗率と患者の脱落問題
3.2.3 市場機会
3.2.3.1 高齢化により有利な成長が見込まれる
3.2.3.2 臨床試験における個別化医療とバイオマーカー開発
3.2.3.3 神経学臨床試験における人工知能と機械学習
3.3 COVID-19インパクト分析
3.4 ポーターのファイブフォース分析
3.4.1 供給者パワー
3.4.2 バイヤーパワー
3.4.3 競合ライバル
3.4.4 代替品による脅威
3.4.5 新規参入の脅威
4 神経学臨床試験市場分析：研究デザイン別
4.1 主な調査結果
4.2 試験デザインセグメント 市場魅力度指数
4.3 研究デザイン別神経学臨床試験市場規模の推定と予測
4.4 インターベンション
4.4.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
4.4.2 2023年および2033年の地域別市場シェア(%)
4.5 観察
4.5.1 2023～2033年の地域別市場予測（US$ Million, AGR %)
4.5.2 2023年および2033年の地域別市場シェア(%)
4.6 アクセス拡大
4.6.1 2023～2033年の地域別市場予測（US$ Million, AGR %)
4.6.2 地域別市場シェア、2023年および2033年 (%)
5 神経学臨床試験市場分析：適応症別
5.1 主な調査結果
5.2 適応症セグメント 市場魅力度指数
5.3 適応症別神経学臨床試験市場規模の推定と予測
5.4 てんかん
5.4.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
5.4.2 2023年および2033年の地域別市場シェア(%)
5.5 脳卒中
5.5.1 2023～2033年の地域別市場予測（US$ Million, AGR %)
5.5.2 2023年および2033年の地域別市場シェア(%)
5.6 アルツハイマー病（AD）
5.6.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
5.6.2 地域別市場シェア、2023年・2033年 (%)
5.7 パーキンソン病（PD）
5.7.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
5.7.2 地域別市場シェア、2023年・2033年 (%)
5.8 外傷性脳障害（TBI）
5.8.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
5.8.2 地域別市場シェア、2023年および2033年 (%)
5.9 その他
5.9.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
5.9.2 地域別市場シェア、2023年・2033年 (%)
6 神経学臨床試験市場分析：フェーズ別
6.1 主要調査結果
6.2 フェーズセグメント 市場魅力度指数
6.3 神経学臨床試験フェーズ別市場規模の推定と予測
6.4 フェーズI
6.4.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
6.4.2 地域別市場シェア、2023年・2033年(%)
6.5 フェーズII
6.5.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
6.5.2 地域別市場シェア、2023年＆2033年(%)
6.6 フェーズ III
6.6.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
6.6.2 地域別市場シェア、2023年＆2033年(%)
6.7 フェーズⅣ
6.7.1 2023〜2033年の地域別市場予測（US$ Million, AGR %)
6.7.2 地域別市場シェア、2023年＆2033年(%)
7 神経内科臨床試験市場分析：地域別
7.1 主要な調査結果
7.2 地域別市場規模の推定と予測
8 北米神経学臨床試験市場分析
8.1 主要な調査結果
8.2 北米の神経学臨床試験市場魅力度指数
8.3 北米の神経学臨床試験市場国別市場規模、2023年、2028年、2033年（US$ Million）
8.4 北米の神経学臨床試験市場規模推定と予測：国別
8.5 北米の神経学臨床試験市場規模推定と予測：試験デザイン別
8.6 北米の神経学臨床試験市場規模推定と予測：適応症別
8.7 北米の神経学臨床試験市場規模推定と予測：フェーズ別
8.8 米国の神経学臨床試験市場分析
8.9 カナダの神経学臨床試験市場分析
9 欧州神経学臨床試験市場分析
9.1 主要な調査結果
9.2 欧州の神経学臨床試験市場魅力度指数
9.3 欧州の神経学臨床試験市場国別市場規模、2023年、2028年、2033年（US$ Million）
9.4 欧州の神経学臨床試験市場規模推定と予測：国別
9.5 欧州の神経学臨床試験市場規模推定と予測：試験デザイン別
9.6 欧州の神経学臨床試験市場規模推定と予測：適応症別
9.7 欧州の神経学臨床試験市場規模推定と予測：フェーズ別
9.8 ドイツの神経学臨床試験市場分析
9.9 イギリスの神経学臨床試験市場分析
9.10 フランスの神経学臨床試験市場分析
9.11 イタリアの神経学臨床試験市場分析
9.12 スペインの神経学の臨床試験市場分析
9.13 その他の欧州の神経学臨床試験市場分析
10 アジア太平洋地域の神経内科臨床試験市場分析
10.1 主要な調査結果
10.2 アジア太平洋地域の神経学臨床試験市場魅力度指数
10.3 アジア太平洋地域の神経学臨床試験市場国別市場規模、2023年、2028年、2033年（US$ Million）
10.4 アジア太平洋地域の神経学臨床試験市場規模推定と予測：国別
10.5 アジア太平洋地域の神経学臨床試験市場規模推定と予測：試験デザイン別
10.6 アジア太平洋地域の神経学臨床試験市場規模推定と予測：適応症別
10.7 アジア太平洋地域の神経学臨床試験市場規模推定と予測：フェーズ別
10.8 日本の神経学臨床試験市場分析
10.9 中国の神経内科臨床試験市場分析
10.10 インドの神経学臨床試験市場分析
10.11 オーストラリアの神経学臨床試験市場分析
10.12 韓国の神経学臨床試験市場分析
10.13 その他のアジア太平洋地域の神経学臨床試験市場分析
11 ラテンアメリカ神経学臨床試験市場分析
11.1 主要な調査結果
11.2 ラテンアメリカの神経学臨床試験市場魅力度指数
11.3 ラテンアメリカの神経学臨床試験国別市場規模、2023年、2028年、2033年（US$ Million）
11.4 ラテンアメリカの神経学臨床試験市場規模推定と予測：国別
11.5 ラテンアメリカの神経学臨床試験市場規模推定と予測：試験デザイン別
11.6 ラテンアメリカの神経学臨床試験市場規模推定と予測：適応症別
11.7 ラテンアメリカの神経学臨床試験市場規模推定と予測：フェーズ別
11.8 ブラジルの神経学臨床試験市場分析
11.9 メキシコの神経学臨床試験市場分析
11.10 その他のラテンアメリカ神経学臨床試験市場分析
12 MEAの神経内科臨床試験市場分析
12.1 主要な調査結果
12.2 MEAの神経学臨床試験市場魅力度指数
12.3 MEAの神経学臨床試験市場国別市場規模、2023年、2028年、2033年（US$ Million）
12.4 MEAの神経学臨床試験市場規模推定と予測：国別
12.5 MEAの神経学臨床試験市場規模推定と予測：試験デザイン別
12.6 MEAの神経学臨床試験市場規模推定と予測：適応症別
12.7 MEAの神経学臨床試験市場規模推定と予測：フェーズ別
12.8 GCCの神経学臨床試験市場分析
12.9 南アフリカの神経学臨床試験市場分析
12.10 その他のMEAの神経学臨床試験市場分析
13 企業のプロフィール
13.1 Biogen
13.1.1 会社概要
13.1.2 会社概要
13.1.3 財務分析
13.1.3.1 純収入、2015-2022年
13.1.3.2 売上高、2015-2022年
13.1.4 製品ベンチマーク
13.1.5 戦略的展望
13.2 AbbVie Inc.
13.2.1 会社概要
13.2.2 会社概要
13.2.3 財務分析
13.2.3.1 純収入、2015-2022年
13.2.3.2 地域市場シェア、2022年
13.2.3.3 R＆D、2015-2022年
13.2.4 製品ベンチマーク
13.2.5 戦略的展望
13.3 Sanofi
13.3.1 会社概要
13.3.2 会社概要
13.3.3 財務分析
13.3.3.1 純収入、2015-2022年
13.3.3.2 地域市場シェア、2022年
13.3.3.3 R＆D、2015-2022年
13.3.4 製品ベンチマーク
13.4 Teva Pharmaceutical Industries Ltd.
13.4.1 会社概要
13.4.2 会社概要
13.4.3 財務分析
13.4.3.1 純収入、2015-2022年
13.4.3.2 地域市場シェア、2022年
13.4.3.3 R＆D、2015-2022年
13.4.4 製品ベンチマーク
13.5 Eli Lilly and Company
13.5.1 企業スナップショット
13.5.1 会社概要
13.5.2 会社概要
13.5.3 財務分析
13.5.3.1 純収入、2015-2022年
13.5.3.2 売上高、2015-2022年
13.5.4 製品ベンチマーク
13.5.5 戦略的展望
13.6 Merck & Co., Inc.
13.6.1 会社概要
13.6.2 会社概要
13.6.3 財務分析
13.6.3.1 純収入、2015-2022年
13.6.3.2 地域市場シェア、2022年
13.6.3.3 R＆D、2015-2022年
13.6.4 製品ベンチマーク
13.7 Eisai Inc.
13.7.1 会社概要
13.7.2 会社概要
13.7.3 財務分析
13.7.3.1 純収入、2015-2022年
13.7.3.2 売上高、2015-2022年
13.7.4 製品ベンチマーク
13.7.5 戦略的展望
13.8 AstraZeneca
13.8.1 会社概要
13.8.2 会社概要
13.8.3 財務分析
13.8.3.1 純収入、2015-2022年
13.8.3.2 地域市場シェア、2022年
13.8.3.3 R＆D、2015-2022年
13.8.4 製品ベンチマーク
13.9 Charles River Laboratories
13.9.1 会社概要
13.9.2 会社概要
13.9.3 財務分析
13.9.3.1 純収入、2015-2022年
13.9.3.2 地域市場シェア、2022年
13.9.4 製品ベンチマーク
13.10 Alector, Inc.
13.10.1 会社概要
13.10.2 会社概要
13.10.3 製品ベンチマーク
13.10.4 戦略的展望
13.11 ICON plc
13.11.1 会社概要
13.11.2 会社概要
13.11.3 財務分析
13.11.3.1 純収入、2015-2022年
13.11.3.2 地域市場シェア、2022年
13.11.4 製品ベンチマーク
13.11.5 戦略的展望
13.12 IQVIA
13.12.1 会社概要
13.12.2 会社概要
13.12.3 財務分析
13.12.3.1 純収入、2015-2022年
13.12.3.2 地域市場シェア、2022年
13.12.4 製品ベンチマーク
13.12.5 戦略的展望
13.13 Labcorp Drug Development
13.13.1 会社概要
13.13.2 会社概要
13.13.3 財務分析
13.13.3.1 純収入、2015-2022年
13.13.4 製品ベンチマーク
13.13.5 戦略的展望
13.14 Medpace Holdings, Inc.
13.14.1 会社概要
13.14.2 会社概要
13.14.3 財務分析
13.14.3.1 純収入、2015-2022年
13.14.4 製品ベンチマーク
13.15 Novartis AG
13.15.1 会社概要
13.15.2 会社概要
13.15.3 財務分析
13.15.3.1 純収入、2015-2022年
13.15.3.2 地域市場シェア、2022年
13.15.3.3 R＆D、2015-2022年
13.15.4 製品ベンチマーク
13.15.5 戦略的展望
13.16 Syneos Health
13.16.1 会社概要
13.16.2 会社概要
13.16.3 財務分析
13.16.3.1 純収入、2015-2022年
13.16.3.2 地域市場シェア、2022年
13.16.4 製品ベンチマーク
13.16.5 戦略的展望
13.17 Annovis Bio
13.17.1 会社概要
13.17.2 会社概要
13.17.3 製品ベンチマーク
13.17.4 戦略的展望
13.18 Supernus Pharmaceuticals, Inc.
13.18.1 会社概要
13.18.2 会社概要
13.18.3 製品ベンチマーク
13.19 Athira Pharma, Inc.
13.19.1 会社概要
13.19.2 会社概要
13.19.3 製品ベンチマーク
14 結論と提言
14.1 Visiongainからの結びの言葉
14.2 市場プレイヤーへの提言
ページTOPに戻る
図表リスト
表の一覧
Table 1 Neurology Clinical Trials Market Snapshot, 2023 & 2033 (US$ million, CAGR %)
Table 2 Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 3 Interventional Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 4 Observational Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 5 Expanded Access Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 6 Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Epilepsy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Stroke Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 Alzheimer's Disease (AD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Parkinson's Disease (PD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Traumatic Brain Injury (TBI) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 Phase I Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Phase II Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Phase III Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Neurology Clinical Trials Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 North America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 North America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 North America Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 North America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 U.S. Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 Canada Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 Europe Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 Europe Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 Europe Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 Europe Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Germany Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 UK Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 31 France Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Italy Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Spain Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Rest of Europe Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 Asia Pacific Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 Asia Pacific Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Asia Pacific Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Asia Pacific Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Japan Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 China Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 India Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Australia Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 South Korea Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Rest of Asia Pacific Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Latin America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 Latin America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 Latin America Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Latin America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 Brazil Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Mexico Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Latin America Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 MEA Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 MEA Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 MEA Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 MEA Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 GCC Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 South Africa Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Rest of MEA Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 60 Biogen: Product Benchmarking
Table 61 Biogen: Strategic Outlook
Table 62 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 63 AbbVie Inc.: Product Benchmarking
Table 64 AbbVie Inc.: Strategic Outlook
Table 65 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 66 Sanofi: Product Benchmarking
Table 67 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 68 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 69 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Eli Lilly and Company: Product Benchmarking
Table 71 Eli Lilly and Company: Strategic Outlook
Table 72 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Merck & Co., Inc.: Product Benchmarking
Table 74 Eisai Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Eisai Inc.: Product Benchmarking
Table 76 Eisai Inc.: Strategic Outlook
Table 77 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 AstraZeneca: Product Benchmarking
Table 79 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Charles River Laboratories: Product Benchmarking
Table 81 Alector, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Alector, Inc.: Product Benchmarking
Table 83 Alector, Inc.: Strategic Outlook
Table 84 ICON plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 ICON plc: Product Benchmarking
Table 86 ICON plc: Strategic Outlook
Table 87 IQVIA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 IQVIA: Product Benchmarking
Table 89 IQVIA: Strategic Outlook
Table 90 Labcorp Drug Development: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Labcorp Drug Development: Product Benchmarking
Table 92 Labcorp Drug Development: Strategic Outlook
Table 93 Medpace Holdings, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Medpace Holdings, Inc.: Product Benchmarking
Table 95 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Novartis AG: Product Benchmarking
Table 97 Novartis AG: Strategic Outlook
Table 98 Syneos Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Syneos Health: Product Benchmarking
Table 100 Syneos Health: Strategic Outlook
Table 101 Annovis Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Annovis Bio: Product Benchmarking
Table 103 Annovis Bio: Strategic Outlook
Table 104 Supernus Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Supernus Pharmaceuticals, Inc.: Product Benchmarking
Table 106 Athira Pharma, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Athira Pharma, Inc.: Product Benchmarking
図の一覧
Figure 1 Neurology Clinical Trials Market Segmentation
Figure 2 Neurology Clinical Trials Market by Study Design: Market Attractiveness Index
Figure 3 Neurology Clinical Trials Market by Indication: Market Attractiveness Index
Figure 4 Neurology Clinical Trials Market by Phase: Market Attractiveness Index
Figure 5 Neurology Clinical Trials Market Attractiveness Index by Region
Figure 6 Neurology Clinical Trials Market: Market Dynamics
Figure 7 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Neurology Clinical Trials Market: Porter’s Five Forces Analysis
Figure 12 Neurology Clinical Trials Market Attractiveness Index by Study Design
Figure 13 Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 14 Neurology Clinical Trials Market Share Forecast by Study Design, 2023, 2028, 2033 (%)
Figure 15 Interventional Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 16 Interventional Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 17 Observational Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 18 Observational Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 19 Expanded Access Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 20 Expanded Access Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 21 Neurology Clinical Trials Market Attractiveness Index by Study Design
Figure 22 Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR %)
Figure 23 Neurology Clinical Trials Market Share Forecast by Indication, 2023, 2028, 2033 (%)
Figure 24 Epilepsy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Epilepsy Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Stroke Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 27 Stroke Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Alzheimer’s Disease (AD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 29 Alzheimer’s Disease (AD) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Parkinson’s Disease (PD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 31 Parkinson’s Disease (PD) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Traumatic Brain Injury (TBI) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 33 Traumatic Brain Injury (TBI) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 35 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 36 Neurology Clinical Trials Market Attractiveness Index by Phase
Figure 37 Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 38 Neurology Clinical Trials Market Share Forecast by Phase, 2023, 2028, 2033 (%)
Figure 39 Phase I Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 40 Phase I Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Phase II Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 42 Phase II Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 43 Phase III Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 44 Phase III Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 45 Phase IV Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 46 Phase IV Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 47 Neurology Clinical Trials Market Forecast by Region 2023, 2028, 2033 (Revenue, CAGR%)
Figure 48 Neurology Clinical Trials Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 49 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Mn)
Figure 50 North America Neurology Clinical Trials Market Attractiveness Index
Figure 51 North America Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 52 North America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 53 North America Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 54 North America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 55 North America Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 56 North America Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 57 North America Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 58 North America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 59 North America Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 60 U.S. Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 61 Canada Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 62 Europe Neurology Clinical Trials Market Attractiveness Index
Figure 63 Europe Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 64 Europe Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 65 Europe Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 66 Europe Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 67 Europe Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 68 Europe Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 69 Europe Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 70 Europe Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 71 Europe Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 72 Germany Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 73 UK Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 74 France Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 75 Italy Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 Spain Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 Rest of Europe Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Asia Pacific Neurology Clinical Trials Market Attractiveness Index
Figure 79 Asia Pacific Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 80 Asia Pacific Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 81 Asia Pacific Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 82 Asia Pacific Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 83 Asia Pacific Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 84 Asia Pacific Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 86 Asia Pacific Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 88 Japan Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 89 China Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 90 India Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 91 Australia Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 92 South Korea Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 Rest of Asia Pacific Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 Latin America Neurology Clinical Trials Market Attractiveness Index
Figure 95 Latin America Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 96 Latin America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 97 Latin America Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 98 Latin America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 100 Latin America Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 101 Latin America Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 102 Latin America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 103 Latin America Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 104 Brazil Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 105 Mexico Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 106 Rest of Latin America Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 107 MEA Neurology Clinical Trials Market Attractiveness Index
Figure 108 MEA Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 109 MEA Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 110 MEA Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 111 MEA Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 112 MEA Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 113 MEA Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 115 MEA Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 116 MEA Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 117 GCC Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 118 South Africa Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 119 Rest of MEA Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 120 Biogen: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 121 Biogen: R&D, 2015-2022 (US$ Million, AGR %)
Figure 122 AbbVie Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 123 AbbVie Inc.: Regional Market Shares (%), 2022
Figure 124 AbbVie Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 125 Sanofi: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 126 Sanofi: Regional Market Shares (%), 2022
Figure 127 Sanofi: R&D, 2015-2022 (US$ Million, AGR %)
Figure 128 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 129 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2022
Figure 130 Teva Pharmaceutical Industries Ltd.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 131 Eli Lilly and Company: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 132 Eli Lilly and Company: R&D, 2015-2022 (US$ Million, AGR %)
Figure 133 Merck & Co., Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 134 Merck & Co., Inc.: Regional Market Shares (%), 2022
Figure 135 Merck & Co., Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 136 Eisai Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 137 Eisai Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 138 AstraZeneca: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 139 AstraZeneca: Regional Market Shares (%), 2022
Figure 140 AstraZeneca: R&D, 2015-2022 (US$ Million, AGR %)
Figure 141 Charles River Laboratories: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 142 Charles River Laboratories: Regional Market Shares (%), 2022
Figure 143 ICON plc: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 144 ICON plc: Regional Market Shares (%), 2022
Figure 145 IQVIA: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 146 IQVIA: Regional Market Shares (%), 2022
Figure 147 Labcorp Drug Development: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 148 Medpace Holdings, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 149 Novartis AG: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 150 Novartis AG: Regional Market Shares (%), 2022
Figure 151 Novartis AG: R&D, 2015-2022 (US$ Million, AGR %)
Figure 152 Syneos Health: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 153 Syneos Health: Regional Market Shares (%), 2022
ページTOPに戻る
Summary
Report Details
The Neurology Clinical Trials Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The implementation of wearable devices, mobile health applications, and remote monitoring tools has brought about a significant paradigm shift in data collection by facilitating the instantaneous monitoring of patient outcomes and the advancement of diseases. These technologies furnish an abundance of ongoing, unbiased data, thereby augmenting the accuracy and dependability of trial outcomes. In addition, developments in neuroimaging methodologies, including functional MRI and PET scans, provide unparalleled perspectives on the operation and interconnections of the brain. The incorporation of technology into the trial process not only enhances efficiency but also provides novel opportunities for comprehending neurological disorders.
What Questions Should You Ask before Buying a Market Research Report?
• How is the neurology clinical trials market evolving?
• What is driving and restraining the neurology clinical trials market?
• How will each neurology clinical trials submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each neurology clinical trials submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading neurology clinical trials markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the neurology clinical trials projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
neurology clinical trials projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the neurology clinical trials market?
• Where is the neurology clinical trials market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the neurology clinical trials market today, and over the next 10 years:
• Our 262-page report provides 107 tables and 153 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the neurology clinical trials market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Study Design
• Interventional
• Observational
• Expanded Access
Indication
• Epilepsy
• Stroke
• Alzheimer’s Disease (AD)
• Parkinson’s Disease (PD)
• Traumatic Brain Injury (TBI)
• Others
Phase
• Phase I
• Phase II
• Phase III
• Phase IV
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe
Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
The report also includes profiles and for some of the leading companies in the Neurology Clinical Trials Market, 2023 to 2033, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
• AbbVie Inc.
• Alector, Inc.
• Annovis Bio
• AstraZeneca
• Athira Pharma, Inc.
• Biogen
• Charles River Laboratories
• Eisai Inc.
• Eli Lilly and Company
• ICON plc
• IQVIA
• Laboratory Drug Development
• Medpace Holdings, Inc.
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Supernus Pharmaceuticals, Inc.
• Syneos Health
• Teva Pharmaceutical Industries Ltd.
Overall world revenue for Neurology Clinical Trials Market, 2023 to 2033 in terms of value the market will surpass US$9,600 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Neurology Clinical Trials Market, 2023 to 2033 report help you?
In summary, our 260+ page report provides you with the following knowledge:
• Revenue forecasts to 2033 for Neurology Clinical Trials Market 2023 to 2033, with forecasts for study design, indication, and phase, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Neurology Clinical Trials Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 19 of the major companies involved in the Neurology Clinical Trials Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Neurology Clinical Trials Market 2023 to 2033, market-leading companies. You will find data, trends and predictions.
ページTOPに戻る
Table of Contents
Table of Contents
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Neurology Clinical Trials Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Prevalence of Neurological Disorders
3.2.1.2 Growing Adoption of Novel Technologies in Clinical Research
3.2.1.3 Significant Number of CROs Providing Neurology Clinical Research Services
3.2.1.4 Increasing Funding for Neurological Studies
3.2.2 Market Restraining Factors
3.2.2.1 High Cost Associated with Neurology Clinical Studies
3.2.2.2 High Failure Rate and Patient Dropout Issues
3.2.3 Market Opportunities
3.2.3.1 Aging Population Projected to Offer Lucrative Growth Prospects
3.2.3.2 Personalised Medicine and Biomarker Development in Clinical Trials
3.2.3.3 Artificial Intelligence and Machine Learning in Neurology Clinical Trials
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
4 Neurology Clinical Trials Market Analysis by Study Design
4.1 Key Findings
4.2 Study Design Segment: Market Attractiveness Index
4.3 Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
4.4 Interventional
4.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
4.4.2 Market Share by Region, 2023 & 2033 (%)
4.5 Observational
4.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
4.5.2 Market Share by Region, 2023 & 2033 (%)
4.6 Expanded Access
4.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
4.6.2 Market Share by Region, 2023 & 2033 (%)
5 Neurology Clinical Trials Market Analysis by Indication
5.1 Key Findings
5.2 Indication Segment: Market Attractiveness Index
5.3 Neurology Clinical Trials Market Size Estimation and Forecast by Indication
5.4 Epilepsy
5.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.4.2 Market Share by Region, 2023 & 2033 (%)
5.5 Stroke
5.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.5.2 Market Share by Region, 2023 & 2033 (%)
5.6 Alzheimer’s Disease (AD)
5.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.6.2 Market Share by Region, 2023 & 2033 (%)
5.7 Parkinson’s Disease (PD)
5.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.7.2 Market Share by Region, 2023 & 2033 (%)
5.8 Traumatic Brain Injury (TBI)
5.8.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.8.2 Market Share by Region, 2023 & 2033 (%)
5.9 Others
5.9.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
5.9.2 Market Share by Region, 2023 & 2033 (%)
6 Neurology Clinical Trials Market Analysis by Phase
6.1 Key Findings
6.2 Phase Segment: Market Attractiveness Index
6.3 Neurology Clinical Trials Market Size Estimation and Forecast by Phase
6.4 Phase I
6.4.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.4.2 Market Share by Region, 2023 & 2033 (%)
6.5 Phase II
6.5.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.5.2 Market Share by Region, 2023 & 2033 (%)
6.6 Phase III
6.6.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.6.2 Market Share by Region, 2023 & 2033 (%)
6.7 Phase IV
6.7.1 Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
6.7.2 Market Share by Region, 2023 & 2033 (%)
7 Neurology Clinical Trials Market Analysis by Region
7.1 Key Findings
7.2 Regional Market Size Estimation and Forecast
8 North America Neurology Clinical Trials Market Analysis
8.1 Key Findings
8.2 North America Neurology Clinical Trials Market Attractiveness Index
8.3 North America Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
8.4 North America Neurology Clinical Trials Market Size Estimation and Forecast by Country
8.5 North America Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
8.6 North America Neurology Clinical Trials Market Size Estimation and Forecast by Indication
8.7 North America Neurology Clinical Trials Market Size Estimation and Forecast by Phase
8.8 U.S. Neurology Clinical Trials Market Analysis
8.9 Canada Neurology Clinical Trials Market Analysis
9 Europe Neurology Clinical Trials Market Analysis
9.1 Key Findings
9.2 Europe Neurology Clinical Trials Market Attractiveness Index
9.3 Europe Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
9.4 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Country
9.5 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
9.6 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Indication
9.7 Europe Neurology Clinical Trials Market Size Estimation and Forecast by Phase
9.8 Germany Neurology Clinical Trials Market Analysis
9.9 UK Neurology Clinical Trials Market Analysis
9.10 France Neurology Clinical Trials Market Analysis
9.11 Italy Neurology Clinical Trials Market Analysis
9.12 Spain Neurology Clinical Trials Market Analysis
9.13 Rest of Europe Neurology Clinical Trials Market Analysis
10 Asia Pacific Neurology Clinical Trials Market Analysis
10.1 Key Findings
10.2 Asia Pacific Neurology Clinical Trials Market Attractiveness Index
10.3 Asia Pacific Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
10.4 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Country
10.5 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
10.6 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Indication
10.7 Asia Pacific Neurology Clinical Trials Market Size Estimation and Forecast by Phase
10.8 Japan Neurology Clinical Trials Market Analysis
10.9 China Neurology Clinical Trials Market Analysis
10.10 India Neurology Clinical Trials Market Analysis
10.11 Australia Neurology Clinical Trials Market Analysis
10.12 South Korea Neurology Clinical Trials Market Analysis
10.13 Rest of Asia Pacific Neurology Clinical Trials Market Analysis
11 Latin America Neurology Clinical Trials Market Analysis
11.1 Key Findings
11.2 Latin America Neurology Clinical Trials Market Attractiveness Index
11.3 Latin America Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
11.4 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Country
11.5 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
11.6 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Indication
11.7 Latin America Neurology Clinical Trials Market Size Estimation and Forecast by Phase
11.8 Brazil Neurology Clinical Trials Market Analysis
11.9 Mexico Neurology Clinical Trials Market Analysis
11.10 Rest of Latin America Neurology Clinical Trials Market Analysis
12 MEA Neurology Clinical Trials Market Analysis
12.1 Key Findings
12.2 MEA Neurology Clinical Trials Market Attractiveness Index
12.3 MEA Neurology Clinical Trials Market by Country, 2023, 2028 & 2033 (US$ Million)
12.4 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Country
12.5 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Study Design
12.6 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Indication
12.7 MEA Neurology Clinical Trials Market Size Estimation and Forecast by Phase
12.8 GCC Neurology Clinical Trials Market Analysis
12.9 South Africa Neurology Clinical Trials Market Analysis
12.10 Rest of MEA Neurology Clinical Trials Market Analysis
13 Company Profiles
13.1 Biogen
13.1.1 Company Snapshot
13.1.2 Company Overview
13.1.3 Financial Analysis
13.1.3.1 Net Revenue, 2015-2022
13.1.3.2 R&D, 2015-2022
13.1.4 Product Benchmarking
13.1.5 Strategic Outlook
13.2 AbbVie Inc.
13.2.1 Company Snapshot
13.2.2 Company Overview
13.2.3 Financial Analysis
13.2.3.1 Net Revenue, 2015-2022
13.2.3.2 Regional Market Shares, 2022
13.2.3.3 R&D, 2015-2022
13.2.4 Product Benchmarking
13.2.5 Strategic Outlook
13.3 Sanofi
13.3.1 Company Snapshot
13.3.2 Company Overview
13.3.3 Financial Analysis
13.3.3.1 Net Revenue, 2015-2022
13.3.3.2 Regional Market Shares, 2022
13.3.3.3 R&D, 2015-2022
13.3.4 Product Benchmarking
13.4 Teva Pharmaceutical Industries Ltd.
13.4.1 Company Snapshot
13.4.2 Company Overview
13.4.3 Financial Analysis
13.4.3.1 Net Revenue, 2015-2022
13.4.3.2 Regional Market Shares, 2022
13.4.3.3 R&D, 2015-2022
13.4.4 Product Benchmarking
13.5 Eli Lilly and Company
13.5.1 Company Snapshot
13.5.2 Company Overview
13.5.3 Financial Analysis
13.5.3.1 Net Revenue, 2015-2022
13.5.3.2 R&D, 2015-2022
13.5.4 Product Benchmarking
13.5.5 Strategic Outlook
13.6 Merck & Co., Inc.
13.6.1 Company Snapshot
13.6.2 Company Overview
13.6.3 Financial Analysis
13.6.3.1 Net Revenue, 2015-2022
13.6.3.2 Regional Market Shares, 2022
13.6.3.3 R&D, 2015-2022
13.6.4 Product Benchmarking
13.7 Eisai Inc.
13.7.1 Company Snapshot
13.7.2 Company Overview
13.7.3 Financial Analysis
13.7.3.1 Net Revenue, 2015-2022
13.7.3.2 R&D, 2015-2022
13.7.4 Product Benchmarking
13.7.5 Strategic Outlook
13.8 AstraZeneca
13.8.1 Company Snapshot
13.8.2 Company Overview
13.8.3 Financial Analysis
13.8.3.1 Net Revenue, 2015-2022
13.8.3.2 Regional Market Shares, 2022
13.8.3.3 R&D, 2015-2022
13.8.4 Product Benchmarking
13.9 Charles River Laboratories
13.9.1 Company Snapshot
13.9.2 Company Overview
13.9.3 Financial Analysis
13.9.3.1 Net Revenue, 2015-2022
13.9.3.2 Regional Market Shares, 2022
13.9.4 Product Benchmarking
13.10 Alector, Inc.
13.10.1 Company Snapshot
13.10.2 Company Overview
13.10.3 Product Benchmarking
13.10.4 Strategic Outlook
13.11 ICON plc
13.11.1 Company Snapshot
13.11.2 Company Overview
13.11.3 Financial Analysis
13.11.3.1 Net Revenue, 2015-2022
13.11.3.2 Regional Market Shares, 2022
13.11.4 Product Benchmarking
13.11.5 Strategic Outlook
13.12 IQVIA
13.12.1 Company Snapshot
13.12.2 Company Overview
13.12.3 Financial Analysis
13.12.3.1 Net Revenue, 2015-2022
13.12.3.2 Regional Market Shares, 2022
13.12.4 Product Benchmarking
13.12.5 Strategic Outlook
13.13 Labcorp Drug Development
13.13.1 Company Snapshot
13.13.2 Company Overview
13.13.3 Financial Analysis
13.13.3.1 Net Revenue, 2015-2022
13.13.4 Product Benchmarking
13.13.5 Strategic Outlook
13.14 Medpace Holdings, Inc.
13.14.1 Company Snapshot
13.14.2 Company Overview
13.14.3 Financial Analysis
13.14.3.1 Net Revenue, 2015-2022
13.14.4 Product Benchmarking
13.15 Novartis AG
13.15.1 Company Snapshot
13.15.2 Company Overview
13.15.3 Financial Analysis
13.15.3.1 Net Revenue, 2015-2022
13.15.3.2 Regional Market Shares, 2022
13.15.3.3 R&D, 2015-2022
13.15.4 Product Benchmarking
13.15.5 Strategic Outlook
13.16 Syneos Health
13.16.1 Company Snapshot
13.16.2 Company Overview
13.16.3 Financial Analysis
13.16.3.1 Net Revenue, 2015-2022
13.16.3.2 Regional Market Shares, 2022
13.16.4 Product Benchmarking
13.16.5 Strategic Outlook
13.17 Annovis Bio
13.17.1 Company Snapshot
13.17.2 Company Overview
13.17.3 Product Benchmarking
13.17.4 Strategic Outlook
13.18 Supernus Pharmaceuticals, Inc.
13.18.1 Company Snapshot
13.18.2 Company Overview
13.18.3 Product Benchmarking
13.19 Athira Pharma, Inc.
13.19.1 Company Snapshot
13.19.2 Company Overview
13.19.3 Product Benchmarking
14 Conclusion and Recommendations
14.1 Concluding Remarks from Visiongain
14.2 Recommendations for Market Players
ページTOPに戻る
List of Tables/Graphs
List of Tables
Table 1 Neurology Clinical Trials Market Snapshot, 2023 & 2033 (US$ million, CAGR %)
Table 2 Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 3 Interventional Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 4 Observational Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 5 Expanded Access Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 6 Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 7 Epilepsy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 8 Stroke Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 9 Alzheimer's Disease (AD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 10 Parkinson's Disease (PD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 11 Traumatic Brain Injury (TBI) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 12 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 13 Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 14 Phase I Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 15 Phase II Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 16 Phase III Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 17 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 18 Neurology Clinical Trials Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 19 North America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 20 North America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 21 North America Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 22 North America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 23 U.S. Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 24 Canada Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 25 Europe Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 26 Europe Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 27 Europe Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 28 Europe Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 29 Germany Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 30 UK Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 31 France Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 32 Italy Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 33 Spain Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 34 Rest of Europe Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 35 Asia Pacific Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 36 Asia Pacific Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 37 Asia Pacific Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 38 Asia Pacific Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 39 Japan Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 40 China Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 41 India Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 42 Australia Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 43 South Korea Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 44 Rest of Asia Pacific Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 45 Latin America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 46 Latin America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 47 Latin America Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 48 Latin America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 49 Brazil Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 50 Mexico Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 51 Rest of Latin America Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 52 MEA Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 53 MEA Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 54 MEA Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 55 MEA Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 56 GCC Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 57 South Africa Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 58 Rest of MEA Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
Table 59 Biogen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 60 Biogen: Product Benchmarking
Table 61 Biogen: Strategic Outlook
Table 62 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 63 AbbVie Inc.: Product Benchmarking
Table 64 AbbVie Inc.: Strategic Outlook
Table 65 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 66 Sanofi: Product Benchmarking
Table 67 Teva Pharmaceutical Industries Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 68 Teva Pharmaceutical Industries Ltd.: Product Benchmarking
Table 69 Eli Lilly and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 70 Eli Lilly and Company: Product Benchmarking
Table 71 Eli Lilly and Company: Strategic Outlook
Table 72 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 73 Merck & Co., Inc.: Product Benchmarking
Table 74 Eisai Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 75 Eisai Inc.: Product Benchmarking
Table 76 Eisai Inc.: Strategic Outlook
Table 77 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 78 AstraZeneca: Product Benchmarking
Table 79 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 80 Charles River Laboratories: Product Benchmarking
Table 81 Alector, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 82 Alector, Inc.: Product Benchmarking
Table 83 Alector, Inc.: Strategic Outlook
Table 84 ICON plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 ICON plc: Product Benchmarking
Table 86 ICON plc: Strategic Outlook
Table 87 IQVIA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 88 IQVIA: Product Benchmarking
Table 89 IQVIA: Strategic Outlook
Table 90 Labcorp Drug Development: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 91 Labcorp Drug Development: Product Benchmarking
Table 92 Labcorp Drug Development: Strategic Outlook
Table 93 Medpace Holdings, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 94 Medpace Holdings, Inc.: Product Benchmarking
Table 95 Novartis AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Novartis AG: Product Benchmarking
Table 97 Novartis AG: Strategic Outlook
Table 98 Syneos Health: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 Syneos Health: Product Benchmarking
Table 100 Syneos Health: Strategic Outlook
Table 101 Annovis Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Annovis Bio: Product Benchmarking
Table 103 Annovis Bio: Strategic Outlook
Table 104 Supernus Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Supernus Pharmaceuticals, Inc.: Product Benchmarking
Table 106 Athira Pharma, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 107 Athira Pharma, Inc.: Product Benchmarking
List of Figures
Figure 1 Neurology Clinical Trials Market Segmentation
Figure 2 Neurology Clinical Trials Market by Study Design: Market Attractiveness Index
Figure 3 Neurology Clinical Trials Market by Indication: Market Attractiveness Index
Figure 4 Neurology Clinical Trials Market by Phase: Market Attractiveness Index
Figure 5 Neurology Clinical Trials Market Attractiveness Index by Region
Figure 6 Neurology Clinical Trials Market: Market Dynamics
Figure 7 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “V” Shaped Recovery
Figure 8 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “U” Shaped Recovery
Figure 9 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “W” Shaped Recovery
Figure 10 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Million, AGR %): “L” Shaped Recovery
Figure 11 Neurology Clinical Trials Market: Porter’s Five Forces Analysis
Figure 12 Neurology Clinical Trials Market Attractiveness Index by Study Design
Figure 13 Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 14 Neurology Clinical Trials Market Share Forecast by Study Design, 2023, 2028, 2033 (%)
Figure 15 Interventional Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 16 Interventional Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 17 Observational Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 18 Observational Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 19 Expanded Access Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 20 Expanded Access Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 21 Neurology Clinical Trials Market Attractiveness Index by Study Design
Figure 22 Neurology Clinical Trials Market Forecast by Indication, 2023-2033 (US$ Million, AGR %)
Figure 23 Neurology Clinical Trials Market Share Forecast by Indication, 2023, 2028, 2033 (%)
Figure 24 Epilepsy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 25 Epilepsy Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 26 Stroke Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 27 Stroke Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 28 Alzheimer’s Disease (AD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 29 Alzheimer’s Disease (AD) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 30 Parkinson’s Disease (PD) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 31 Parkinson’s Disease (PD) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 32 Traumatic Brain Injury (TBI) Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 33 Traumatic Brain Injury (TBI) Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 34 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 35 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 36 Neurology Clinical Trials Market Attractiveness Index by Phase
Figure 37 Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 38 Neurology Clinical Trials Market Share Forecast by Phase, 2023, 2028, 2033 (%)
Figure 39 Phase I Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 40 Phase I Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 41 Phase II Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 42 Phase II Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 43 Phase III Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 44 Phase III Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 45 Phase IV Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
Figure 46 Phase IV Segment Market Share Forecast by Region, 2023 & 2033 (%)
Figure 47 Neurology Clinical Trials Market Forecast by Region 2023, 2028, 2033 (Revenue, CAGR%)
Figure 48 Neurology Clinical Trials Market Share Forecast by Region 2023, 2028, 2033 (%)
Figure 49 Neurology Clinical Trials Market by Region, 2023-2033 (US$ Mn)
Figure 50 North America Neurology Clinical Trials Market Attractiveness Index
Figure 51 North America Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 52 North America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 53 North America Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 54 North America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 55 North America Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 56 North America Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 57 North America Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 58 North America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 59 North America Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 60 U.S. Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 61 Canada Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 62 Europe Neurology Clinical Trials Market Attractiveness Index
Figure 63 Europe Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 64 Europe Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 65 Europe Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 66 Europe Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 67 Europe Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 68 Europe Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 69 Europe Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 70 Europe Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 71 Europe Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 72 Germany Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 73 UK Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 74 France Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 75 Italy Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 76 Spain Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 77 Rest of Europe Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 78 Asia Pacific Neurology Clinical Trials Market Attractiveness Index
Figure 79 Asia Pacific Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 80 Asia Pacific Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 81 Asia Pacific Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 82 Asia Pacific Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 83 Asia Pacific Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 84 Asia Pacific Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 85 Asia Pacific Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 86 Asia Pacific Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 87 Asia Pacific Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 88 Japan Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 89 China Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 90 India Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 91 Australia Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 92 South Korea Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 93 Rest of Asia Pacific Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 94 Latin America Neurology Clinical Trials Market Attractiveness Index
Figure 95 Latin America Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 96 Latin America Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 97 Latin America Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 98 Latin America Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 99 Latin America Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 100 Latin America Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 101 Latin America Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 102 Latin America Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 103 Latin America Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 104 Brazil Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 105 Mexico Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 106 Rest of Latin America Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 107 MEA Neurology Clinical Trials Market Attractiveness Index
Figure 108 MEA Neurology Clinical Trials Market by Region, 2023, 2028 & 2033 (US$ million)
Figure 109 MEA Neurology Clinical Trials Market Forecast by Country, 2023-2033 (US$ million)
Figure 110 MEA Neurology Clinical Trials Market Share Forecast by Country, 2023 & 2033 (%)
Figure 111 MEA Neurology Clinical Trials Market Forecast by Study Design, 2023-2033 (US$ Million, AGR %)
Figure 112 MEA Neurology Clinical Trials Market Share Forecast by Study Design, 2023 & 2033 (%)
Figure 113 MEA Neurology Clinical Trials Market Forecast by Indication , 2023-2033 (US$ Million, AGR %)
Figure 114 MEA Neurology Clinical Trials Market Share Forecast by Indication , 2023 & 2033 (%)
Figure 115 MEA Neurology Clinical Trials Market Forecast by Phase, 2023-2033 (US$ Million, AGR %)
Figure 116 MEA Neurology Clinical Trials Market Share Forecast by Phase, 2023 & 2033 (%)
Figure 117 GCC Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 118 South Africa Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 119 Rest of MEA Neurology Clinical Trials Market Forecast, 2023-2033 (US$ Million, AGR %)
Figure 120 Biogen: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 121 Biogen: R&D, 2015-2022 (US$ Million, AGR %)
Figure 122 AbbVie Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 123 AbbVie Inc.: Regional Market Shares (%), 2022
Figure 124 AbbVie Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 125 Sanofi: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 126 Sanofi: Regional Market Shares (%), 2022
Figure 127 Sanofi: R&D, 2015-2022 (US$ Million, AGR %)
Figure 128 Teva Pharmaceutical Industries Ltd.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 129 Teva Pharmaceutical Industries Ltd.: Regional Market Shares (%), 2022
Figure 130 Teva Pharmaceutical Industries Ltd.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 131 Eli Lilly and Company: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 132 Eli Lilly and Company: R&D, 2015-2022 (US$ Million, AGR %)
Figure 133 Merck & Co., Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 134 Merck & Co., Inc.: Regional Market Shares (%), 2022
Figure 135 Merck & Co., Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 136 Eisai Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 137 Eisai Inc.: R&D, 2015-2022 (US$ Million, AGR %)
Figure 138 AstraZeneca: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 139 AstraZeneca: Regional Market Shares (%), 2022
Figure 140 AstraZeneca: R&D, 2015-2022 (US$ Million, AGR %)
Figure 141 Charles River Laboratories: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 142 Charles River Laboratories: Regional Market Shares (%), 2022
Figure 143 ICON plc: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 144 ICON plc: Regional Market Shares (%), 2022
Figure 145 IQVIA: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 146 IQVIA: Regional Market Shares (%), 2022
Figure 147 Labcorp Drug Development: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 148 Medpace Holdings, Inc.: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 149 Novartis AG: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 150 Novartis AG: Regional Market Shares (%), 2022
Figure 151 Novartis AG: R&D, 2015-2022 (US$ Million, AGR %)
Figure 152 Syneos Health: Net Revenue, 2015-2022 (US$ Million, AGR %)
Figure 153 Syneos Health: Regional Market Shares (%), 2022
ページTOPに戻る
Visiongain社の医薬・化学品分野での最新刊レポート
本レポートと同じKEY WORD（brain injury）の最新刊レポート
よくあるご質問
Visiongain社はどのような調査会社ですか?
英国の調査会社ヴィジョンゲイン社（Visiongain）は、通信とエネルギーのほか、自動車や化学・医薬品、金属など、広範な市場を対象に調査を行っています。自動車市場については、市場全般に関する調査のほ... もっと見る
調査レポートの納品までの日数はどの程度ですか?
在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。
注文の手続きはどのようになっていますか?
1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。
お支払方法の方法はどのようになっていますか?
納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。
データリソース社はどのような会社ですか?
当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。
|
|
